HBV Infection Can Not Cure Why Should We Treat Now

The development of chronic hepatitis B treatment is still a major challenge, because the treatment of HBV infection is currently only limited to viral suppression and disease control with ongoing treatment for life. This is due to the inability to eliminate cccDNA HBV and partial recovery of immune response defects. currently offered is reducing viral load, increasing immune response and revising therapeutic endpoint targets from sterile cure to functional cure that is currently considered rational and ideal targets, by using a combinatorial strategy DAA (NA) and immunomodulator (PEG-IFN). Besides suppressing HBV replication, Nucleos(t)ide Analogue (NA) can also restore the adaptive immune response, while PEG-IFN can stimulate innate immune responses. PEG-IFN has dual effects, increases the production of Interferon stimulated Gen (ISG) which will encode antiviral proteins and can inhibit HBV transcription by increasing HBV RNA pregenomic (pgRNA) degradation by modifying the cccDNA epigenetic regulation. Post treatment HBs Ag loss should be monitored levels of qHBsAg, HBV DNA, ALT and qHBcrAg annually. In future to achieve sterile cure, combination therapy research that is targeted at various stages of the HBV life cycle is needed.